{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:53:20Z","timestamp":1792810400014,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We have shown that viral load kinetics during the first cytomegalovirus (CMV) viremic episode are important predictors of kidney transplant failure. This article evaluates the incremental hazard of recurrent CMV viremia and of viral load kinetics on graft and patient survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included 2,464 sequential kidney transplants performed between 2008 and 2018. Care was delivered according to a uniform provincial protocol, and patients were followed for up to 13 years with standardized therapy and continuous monitoring of clinical course, CMV infection, viral load kinetics, and graft and patient outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>434\/2,464 (17.6%) patients (age range: 2\u201380 years) developed CMV infection, of whom 67\/434 (15.4%) had 150 episodes of recurrent infection. Mean cumulative CMV frequency reached an asymptote of 21% at 500 days, with the highest rate (43%) in D+\/R-, and lowest (1%) in D-\/R- risk groups. Multinomial adjusted regression described a composite risk phenotype that included increased age, non-Caucasian race, diabetes, D+\/R- status, and delayed graft function (<jats:italic>p<\/jats:italic>&amp;lt;0.005). Median cumulative viral load kinetic values rose progressively with the number of viremic episodes, maximum viral load rising from 3.8\u20135.1 log<jats:sub>10<\/jats:sub> IU\/mL, mean duration of viremia from 15\u2013116 days, and viral AUC from 56.1\u2013492.9 log<jats:sub>10<\/jats:sub> IU\/mL*days in patients with multiple episodes of CMV viremia. Predicted probability of graft failure and death were closely related to the cumulative duration of viremia and total viral load, with respective survival values declining to 30% and 7% in patients with elevated viremic indices and defined composite risk phenotype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with a recurrent CMV viremia post-transplant are at exceptionally high risk of transplant failure as measured by graft loss or death, which is determined by both composite risk phenotype and CMV viral load kinetics. Conventional prophylaxis appears to be inadequate to protect these patients from recurrent infection and its serious consequences, and alternative treatment strategies, with continuous long-term monitoring and rapid, effective therapy, are vital to maximize transplant success.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1600289","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T10:37:21Z","timestamp":1754649441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation"],"prefix":"10.3389","volume":"16","author":[{"given":"Sabina","family":"Dobrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Sherwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Matic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Keown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13483","article-title":"Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: a systematic literature review of real-world evidence","volume":"23","author":"Raval","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-1111-1_1","article-title":"Overview of human cytomegalovirus pathogenesis","volume":"2244","author":"Fulkerson","year":"2021","journal-title":"Methods Mol Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003887","article-title":"The clinical and economic benefit of CMV matching in kidney transplant: a decision analysis","volume":"106","author":"Axelrod","year":"2022","journal-title":"Transplantation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa249","article-title":"Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention","volume":"37","author":"Hellemans","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15183","article-title":"Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: a paired kidney analysis","volume":"19","author":"Leeaphorn","year":"2019","journal-title":"Am J Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14583","article-title":"Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia","volume":"36","author":"Brar","year":"2022","journal-title":"Clin Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1302627","article-title":"Viral load kinetics and the clinical consequences of cytomegalovirus in kidney transplantation","volume":"14","author":"Dobrer","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jviromet.2017.11.001","article-title":"Results of cytomegalovirus DNA viral loads expressed in copies per millilitre and international units per millilitre are equivalent","volume":"252","author":"Dimech","year":"2018","journal-title":"J Virol Methods"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis212","article-title":"Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective","volume":"54","author":"Kraft","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03292-15","article-title":"Commutability of cytomegalovirus WHO international standard in different matrices","volume":"54","author":"Jones","year":"2016","journal-title":"J Clin Microbiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003774.pub5","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"5","author":"Vernooij","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17171","article-title":"Antiviral toxicities in pediatric solid organ transplant recipients","volume":"22","author":"Hayes","year":"2022","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant\/refractory disease","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.2147\/DDDT.S265644","article-title":"Current perspectives on letermovir and maribavir for the management of cytomegalovirus infection in solid organ transplant recipients","volume":"18","author":"Razonable","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12874-020-01115-7","article-title":"Assessing risk of bias: a proposal for a unified framework for observational studies and randomized trials","volume":"20","author":"Luijendijk","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00078","article-title":"Cytokine-mediated induction and regulation of tissue damage during cytomegalovirus infection","volume":"10","author":"Clement","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9856","article-title":"Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function","volume":"6","author":"Sen","year":"2020","journal-title":"Sci Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01155","article-title":"Subversion of immune response by human cytomegalovirus","volume":"10","author":"Patro","year":"2019","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181949e09","article-title":"Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines","volume":"87","author":"Dmitrienko","year":"2009","journal-title":"Transplantation"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1600289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T10:37:21Z","timestamp":1754649441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1600289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1600289"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1600289","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"1600289"}}